Loading...
By Amy Orciari Herman
Edited by Susan Sadoughi, MD
The FDA is investigating a potentially increased risk for leg and foot amputations among patients taking the diabetes drug canagliflozin. The sodium-glucose cotransporter-2 inhibitor is sold under the brand names Invokana and, in combination with metformin, Invokamet.
An interim analysis from the Canagliflozin Cardiovascular Assessment Study found roughly twice the risk for leg and foot amputations with the drug than with placebo. In particular, the 1-year amputation rate was 7 per 1000 patients treated with 100-mg canagliflozin and 5 per 1000 treated with 300 mg, versus 3 per 1000 receiving placebo.
However, a separate ongoing trial of canagliflozin has not shown a similar risk increase.
While the drug is being investigated, the FDA says, clinicians should continue prescribing the drug according to the label and monitor patients for leg and foot symptoms including new pain or tenderness, sores, or infections. Side effects should be reported to the FDA's MedWatch program at the link below.
Comment
LINK(S):
FDA MedWatch safety alert (Free)
Background: Physician's First Watch coverage of safety warnings being added to canagliflozin and other SGLT2 inhibitors (Free)